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Introduction
Coffee is amongst the most widely consumed and available beverages in the world [1] , which has fuelled increasing public and scientific interest in the potential health consequences of its regular consumption.
Accumulating epidemiological research of coffee supports inverse linear associations with mortality [2] , incident type 2 diabetes (T2D) [3] and Parkinson's disease [4] . A protective association with moderate coffee consumption has also been reported for incident cardiovascular disease (CVD) [5] . Experimental studies support neuroprotective, anti-inflammatory, antioxidant and anti-adipogenic properties of coffee [6] [7] [8] [9] [10] , but mechanisms underlying the potential protective health effects of coffee in humans remain unclear. Coffee has also been implicated in a variety of other diseases, attributing beneficial as well as adverse effects [11, 12] . For many populations, coffee is the primary source of dietary caffeine [13, 14] , the most studied component of this beverage. However, coffee is also a major source of hundreds of other biologically active components, such as diterpenes, chlorogenic acids, flavonoids, hydroxycinnamic acids, tocopherols and melanoidins [15, 16] , which might modify the effects of caffeine or independently influence disease-related pathways.
Recent advances in proteomics methodologies provide an opportunity to move the field of coffee research forward [12] . Indeed, using populationbased genomic, metabolomic and broad multimarker analyses, we and others have discovered novel and biologically plausible pathways correlated with habitual coffee consumption [12, 17, 18 ]. In the current study, we aimed to further the understanding of downstream effects of coffee intake in humans using a highly sensitive and specific proteomics assay to identify habitual coffee-induced changes of up to 80 protein markers associated with CVD in three Swedish large population-based cohorts, the Prospective Study of the Vasculature in Uppsala Seniors (PIVUS), Uppsala Longitudinal Study of Adult Men (ULSAM) and EpiHealth.
Materials and methods

Study samples
Prospective Study of the Vasculature in Uppsala Seniors (PIVUS) All 70-year-old individuals living in Uppsala, Sweden, in 2001-2004 were eligible for PIVUS, and 2025 randomly selected individuals were invited within 2 months of their 70th birthday from April 2001 to June 2004. Of these, 1016 (50%) participated in the study. The study has been described in detail previously [19, 20] . Participants were similar to nonparticipants with regard to cardiovascular health and medication use [19] . In brief, at the baseline examination, the participants underwent a blood pressure measurement and anthropometry, blood sampling after an overnight fast, routine medical history, questionnaire and a seven-day diet registration. The latter was added to the study protocol after study initiation when about 10-15% of participants had already completed the assessment. Of the 1016 PIVUS participants, we excluded 170 individuals that lacked information on coffee intake, 19 individuals without blood samples or who did not pass the proteomics quality control (QC) process, one individual missing covariate data for the main regression model, and ten individuals with plasma C-reactive protein levels exceeding 20 mg L
À1
. Hence, the sample size for the present study was 816 (Table 1, Table S1 ).
Uppsala Longitudinal Study of Adult Men (ULSAM)
ULSAM was initiated in 1970, when all men 50 years of age and born between 1920 and 1924 in Uppsala, Sweden were invited to participate (2322 participated of 2841 invited; participation rate = 82%). Participants have been followed up at the ages of 60, 70, 77, 82 and 88 years. The study has been described previously [21, 22] . This study is based on the examinations performed at ages 70 (n = 1221; participation rate = 73%), when diet was assessed, and 77 years (n = 839; participation rate = 60%), when fasting plasma for proteomics was available. Of the 766 ULSAM participants that participated in both the age 70 and age 77 examinations, we excluded 20 individuals that lacked information on coffee intake, 69 individuals without blood samples or who did not pass the proteomics QC process, 26 individuals missing covariate data for the main regression model and 16 individuals with plasma C-reactive protein levels exceeding 20 mg L
À1
. Hence, the sample size for the present study was 635 (Table 1, Table S1 ).
EpiHealth
The Swedish EpiHealth cohort study was initiated in 2011 with the goal of recruiting 300 000 men and women aged 45-75 years in the Swedish towns of Uppsala and Malm€ o [23] . As of 1 January 2013 >7000 participants had been included in the study, with a participation rate~25% [23] . The study consists of three parts: a collection of selfreported data on lifestyle by internet-based questionnaires; a clinical visit where blood samples are collected and physiological parameters recorded; and follow-up for occurrence of outcomes using nationwide medical registers. This study is based on a random sample of 2500 individuals providing a fasting (94%) or nonfasting (6%) blood sample. Of this sample, 82 were excluded due to low quality data from either proteomic assay or missing coffee or covariate data, leaving up to 2418 for the final analysis (Table 1, Table S1 ).
Exposure assessment
Coffee consumption Seven-day dietary records were collected from PIVUS participants in 2001-2004 after the examination and thus close to the time blood samples were drawn for proteomic analysis, whilst the seven-day dietary records in ULSAM were collected in 1990-1994, about 7 years before blood collection for proteomic analysis. Coffee intake was recorded six times daily (breakfast, lunch, supper, between meals and in the evening) in millilitres [24] . EpiHealth participants completed a computer-based food frequency questionnaire approximately 2-3 weeks prior to the clinical visit [23] . Participants were asked for the number of times per day that coffee was consumed over the past 12 months and were provided response options ranging from none and 1-5 or more times per day. Volume (cup size) of coffee was not collected.
For PIVUS and ULSAM analysis, we derived the number of cups of coffee consumed per day assuming a cup volume of 150 mL. For EpiHealth, we modelled the number of times coffee was consumed which ranged from 0 to 5 times per day. Type of coffee (i.e. regular, decaffeinated) or method of preparation (filtered, boiled) was not recorded, but decaffeinated coffee is very unusual in Sweden (<1%), and the majority of coffee was filtered in Sweden before the late 2000-ies [25] . A subset of ULSAM participants (N = 242) provided a second set of seven-day dietary records at the age 82 exam (~12 years after the first). The overall mean intake decreased from 3.4 to 2.7 cups day À1 but coffee intake at the two time-points were correlated (r = 0.54, P < 0.0001), and this is Multiplex CVD I 96996 kit (http://www.olink.com/ products/document-download-center/), measuring 92 selected cardiovascular disease-related proteins simultaneously. The kit is based on the proximity extension assay (PEA) technology, where 92 oligonucleotide-labelled antibody probe pairs are allowed to bind to their respective target present in the sample [29, 30] . The PEA technique has a major advantage over conventional multiplex immunoassays in that only correctly matched antibody pairs give rise to a signal, yielding an exceptionally high specificity. In addition, as it is a PCR-based methodology, it is also very sensitive. The amplicons are quantified on a Fluidigm BioMark TM HD real-time PCR platform. All assay runs include internal controls for monitoring incubation, extension and detection. An inter-plate control (external/technical control) is set in triplicate on each plate and used for normalization. Sample quality is assessed by evaluation of the deviation from the median value for the incubation and detection controls. A sample will fail quality control if controls deviate more than AE0.3 from the median value of all samples. The quality of the entire run is evaluated by calculating the standard deviations of incubation and detection controls and should be below the predetermined quality threshold 0.2. All panel assay characteristics including list of protein markers, detection limits and measurements of assay performance and validations are available from the manufacturer (http://www. olink.com/products/document-download-center/ ). The platform provides normalized protein expression (NPX) data where a high protein value corresponds to a high protein concentration, but not an absolute quantification. The Proseek â Multiplex CVD I 96996 has been shown to have high reproducibility and repeatability with mean intra-assay and inter-assay coefficients of variation of 8% and 12%, respectively; and the average inter-site variation has been reported to be 15% [29] . All samples and runs for PIVUS and ULSAM passed technical quality control. Twelve proteins with a call rate <85% (i.e. <85% of the individuals had a valid measurement of that specific protein) in PIVUS and/or ULSAM were removed from further analysis, including IL-4, melusin, BNP, Beta-NGF, SIRT2, NEMO, mAmP, PTX3, NT-pro-BNP, MMP-7, cystatin-B and heat shock 27 kDa protein.
Hence, 80 proteins present in both studies were taken forward for analysis (Table S2) . Individuals with excess missingness based on visual inspection of a histogram were excluded (>5% and >3% in PIVUS and ULSAM, respectively). Each protein was normalized by plate (by setting the mean = 0 and standard deviation = 1 within each plate) and further by storage time (correction based on the observed values and predicted values from a spline model).
EpiHealth analyses were performed using the Olink Proseek â Multiplex CVD II and III 96996 kits which together include~70% of the CVD I protein content. The mean intra-assay and inter-assay coefficients of variation for the CVD II panel are 9% and 12%, respectively. Corresponding CVs for CVD III are 8% and 11%. Samples that (i) failed for technical reasons on both chips or (ii) a sample call rate <0.95 on either chip were excluded. Proteins with ≥10% missingness were also excluded. Each protein was normalized by plate.
Statistical analysis
The CVD I assay proteins were prioritized because they were available for both PIVUS and ULSAM which also collected more precise coffee consumption data. Of these two studies, the PIVUS study was a priori designated discovery cohort as it was larger, included both men and women, and the coffee assessment was performed at the time of blood draw. Linear regression models were used with the number of cups of coffee per day as independent variable and the 80 proteins captured by the CVD I assay as dependent variables in separate models (one per protein marker). Primary models were adjusted for age, sex, date of blood draw, current smoking and body mass index (BMI). For protein markers with a false discovery rate (FDR; estimated using the Benjamini & Hochberg method [31] ) <5% in PIVUS, we attempted replication using the same statistical model in ULSAM and, if proteins were available in the CVD II or CVD III kits, EpiHealth. We considered protein markers showing a nominally significant P-value (P < 0.05) to be successfully replicated. Given the correlation structure across protein markers with many proteins displaying high correlations ( Fig. 1) and that we only brought four markers forward for replication, this replication strategy should be considered to be on the conservative side minimizing falsepositive findings. For protein markers that were successfully replicated, we performed secondary analyses including additional adjustment for waist-hip ratio (WHR, all studies), %BF (PIVUS, EpiHealth), physical activity (all studies), additional smoking categories (EpiHealth), consumption of alcohol (all studies) and dietary fat (PIVUS and ULSAM), and the addition of cream/sugar to coffee (EpiHealth). No evidence of multicollinearity was observed when these additional covariates were added to the model (no variance inflation factors exceeded 1.1). For 760 PIVUS participants, plasma caffeine was measured by UPLC-MS/MS using samples collected at the same time-point as those used for proteomics [32] . Proteins significantly associated with coffee intake were further explored for associations with plasma caffeine by multivariate linear regression. Results when modelling coffee consumption as a categorical exposure were also evaluated. Additionally, we performed an inverse variance meta-analysis assuming fixed effects of the CVD I results from the PIVUS and ULSAM studies. Protein biomarkers with a FDR <5% from this meta-analysis (which maximized the statistical power for discovery of novel associations) were considered suggestive and worthy of future additional studies. To investigate the role of sex and BMI as potential effect modifiers, we also performed analyses stratified by sex (in PIVUS only, as all participants in ULSAM were men) and BMI [normal-weight (<25 kg m À2 ) vs. overweight and obese (≥25 kg m À2 )] and tested for potential effect modification with a t-test based on the interaction term estimate from the full regression model. All analyses were performed using Stata 13.1 (Stata Corp, College Station, TX, USA) or R 3.2.2 [33] .
Results
The clinical and lifestyle characteristics of the three study samples are shown in Table 1 . Compared to the discovery cohort (PIVUS), the ULSAM population was all men, older, had lower BMI, but less favourable body composition and lipid profile, higher blood pressure, and more likely to be taking antihypertension medication and have diabetes or prior CVD. EpiHealth was younger and less likely to be taking lipid lowering and antihypertension medication and have diabetes or prior CVD compared to PIVUS. Table S1 presents characteristics of the PIVUS and ULSAM participants by coffee consumption. In both studies, heavy coffee drinkers were more likely to be smokers and to have less favourable plasma cholesterol profiles compared to lighter drinkers. They were also less likely to be taking antihypertension medication and to have lower plasma glucose levels compared to lighter drinkers. In PIVUS, heavy coffee drinkers were also more likely to be men compared to lighter drinkers. In ULSAM, heavy coffee drinkers had a less favourable body composition compared to lighter drinkers.
Four of the 80 proteins measured were significantly associated with coffee consumption in PIVUS (FDR < 5%, P < 2.31 9 10
À3
) and were carried forward for replication in ULSAM and EpiHealth ( Table 2, Table S2 ). These included leptin (LEP), chitinase-3-like protein 1 (CHI3L1), tumour necrosis factor receptor superfamily member 6 (FAS) and TNF-related apoptosis-inducing ligand (TRAIL, not available in EpiHealth). Primary discovery results were similar when replacing missing protein values [those below the lower limit of detection (LOD)] with LOD/2 (data not shown). Of the four significantly associated proteins, only LEP replicated in both ULSAM and EpiHealth (P < 0.03, Table 2 ). When linear regression models were further adjusted for WHR, the association between coffee consumption and LEP was slightly attenuated in PIVUS (b = À0.039, P = 0.001), augmented in ULSAM (b = À0.05, P = 0.009) and unchanged in EpiHealth (b = À0.025, P = 0.003). %BF was measured in PIVUS and EpiHealth only and adjusting for this variable attenuated the coffee-LEP association in both cohorts (PIVUS: b = À0.025, P = 0.03, EpiHealth: b = À0.012, P = 0.11). No significant adiposity-coffee interactions were Fig. 1 Correlation matrix of all examined protein markers. Partial Pearson's correlation coefficients were calculated between each pair of proteins separately in PIVUS and ULSAM with adjustment for age (and sex in PIVUS). Correlation coefficients were then transformed using Fisher's r-to-Z transformation and combined for PIVUS and ULSAM in an inversevariance weighted meta-analysis. Meta-analyses results where then back-transformed from Z-to-r and ordered using hierarchical clustering.
observed. Adjustment for other lifestyle factors or when coffee consumption was modelled as a categorical variable yielded similar results to those of our primary model (data not shown). Leptin has also previously been measured in PIVUS by double antibody radioimmunoassay (RIA) method (Linco Res, St Louis, MO, USA). The latter was highly correlated with leptin measured by the proximity extension assay in the current study (Pearson r = 0.93), and it was also associated with coffee consumption (b = À0.043, P < 0.001 for the primary regression model).
The inverse coffee-CHI3L1 association replicated in EpiHealth (P = 1.15 9 10 À7 ). Although the inverse coffee-CHI3L1 association was not statistically significant in ULSAM (P = 0.16), statistical significance was met in a meta-analysis of PIVUS and ULSAM (FDR < 5%, Table S2 ). Coffee-CHI3L1 associations were similar when further adjusting for additional measures of adiposity and lifestyle, or when coffee consumption was modelled as a categorical variable (data not shown). The results in Table 2 were also similar for EpiHealth when nonfasting samples were excluded (data not shown). In PIVUS and EpiHealth, LEP (P < 0.02) and CHI3L1 (P < 0.002) were independently associated with coffee intake when modelled simultaneously. In ULSAM, the significant association between coffee intake and LEP was attenuated after adjusting for CHI3L1 (P = 0.05).
In the subset of PIVUS participants with plasma caffeine data, we observed opposite patterns of associations between plasma caffeine and proteins compared to those observed between coffee intake and proteins: higher plasma caffeine levels were significantly associated with higher CHI3L1 (P < 0.0001) levels and weakly associated with higher LEP levels (P = 0.08). When coffee intake was modelled with plasma caffeine, both coffee intake and plasma caffeine remained significantly associated with CHI3L1 (both predictors P < 0.0001). Applying the same model, coffee intake and plasma caffeine were significantly associated with LEP levels (P < 0.0001 and P = 0.01, respectively). In this sample, coffee intake was positively associated with plasma caffeine levels (P < 0.0001).
In sex-stratified analysis of PIVUS (Table S3) , FAS and TRAIL were significantly associated with coffee intake in men (FDR < 0.05). However, no significant sex-coffee interaction was observed and these associations did not replicate in ULSAM (all men) or EpiHealth. No additional and meaningful sexcoffee interactions were observed. Furthermore, no Associations with a false discovery value (FDR < 5%) in the discovery cohort (PIVUS). b Values are betas (standard errors, SE) from linear regression models with number of cups of coffee per day as independent variable and the four proteins as dependent variables in separate models (one per protein marker). All models were adjusted for age, sex (PIVUS only), smoking and BMI. The beta coefficients represent increase of Z-score standardized protein levels per additional cup of coffee per day. c Values are betas (SE) from linear regression models with number of times coffee was consumed per day as independent variable and the three proteins as dependent variables in separate models (one per protein marker). All models were adjusted for age, sex, date of blood draw, smoking and BMI. The beta coefficients represent increase of Z-score standardized protein levels per additional time (occasion) of coffee consumed per day.
coffee-protein associations were observed in BMIstratified analysis and, accordingly, no significant BMI-coffee interactions for protein levels were evident (Table S4) .
Discussion
The application of proteomics methodologies to studies of coffee in populations has revealed biologically plausible, as well as novel pathways correlated with habitual coffee consumption [12, 17, 18 ]. In the current study, we extend this literature to the proteome, targeting 80 protein markers implicated in CVD and potentially other diseases. In three Swedish populations, coffee intake was associated with lower leptin and CHI3L1 levels.
To our knowledge, only one previous study has examined the association between habitual coffee intake and a broad set of protein markers. Loftfield et al. [17] measured serum levels of 77 immune and inflammatory markers by Luminex beadbased assays in 1728 non-Hispanic Whites aged 55-74 from the population-based Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. They reported significant associations between coffee consumption and five proteins (IFNc, CX3CL1/fractalkine, CCL4/MIP-1b, sTNFRII and FGF-2). Of these five, the current study examined CCL4/MIP-1b and sTNFRII, and the strongest association amongst these two (data available for PIVUS and ULSAM only) was observed in ULSAM only: coffee intake was subnominally associated with sTNFRII (P = 0.06) and in the direction consistent with that reported by Loftfield et al. [17] . The coffee consumption distribution in this US based population, the absence of independent replication (thus, higher risk of chance findings) and the analytical model (dichotomized protein levels and categorical coffee exposure) employed by Loftfield et al. [17] may have contributed to discrepant findings between that study and the current study.
In PIVUS, ULSAM and EpiHealth, higher coffee consumption was significantly associated with lower leptin levels. Leptin is released in response to increasing adiposity and functions to decrease appetite and induce satiety [34, 35] . Although data are limited, habitual caffeine and coffee intake have been linked to moderate weight loss in humans [36, 37] . In animals, chronic feeding of caffeine and other coffee constituents lowers leptin levels, suppresses fat accumulation and body weight gain [9, 38] . Indeed, further model adjustment for %BF attenuated the association between coffee and leptin in PIVUS and EpiHealth (%BF was not available in ULSAM), supporting potential mediation (or confounding) by adiposity. Potential for a link between coffee intake and leptin levels is further iterated by the fact that associations between this beverage and leptin have been investigated by six population-based studies, sample sizes ranging from 375 to 5600 [17, [39] [40] [41] [42] [43] . Three of these, all in Japanese populations, support the primary findings of the current study [39] [40] [41] . In contrast, three report no association between coffee consumption and leptin levels [17, 42, 43] . Of the latter, Marques-Vidal et al. [42] examined a Swiss population and combined total coffee and energy drinks for analysis. Their primary statistical models also included waist, hip and body fat mass; potential mediators of the association between coffee and leptin, rendering direct comparison with our primary results difficult. Measures of leptin were dichotomized for the analysis conducted by Loftfield et al. [17] which may have reduced study power. The third and most recent study tested leptin and 20 other inflammatory biomarkers for associations with coffee consumption in 125 liver cancer cases and 250 controls [43] . Sample size or between-study differences in the distribution of coffee consumption and obesity as well as the correlation amongst these traits may account for discrepancies across studies. Leptin circulates in the free or protein-bound form [44, 45] . Levels of the free form purportedly relate to changes in fat mass, whereas boundleptin is related to energy expenditure and muscle sympathetic nerve activity [45, 46] . Antibodies used in the current study target either forms but likely favour free leptin as the antigens of this form are more accessible to the antibodies than for protein bound leptin. Previous studies of coffee intake and leptin have employed ELISA [42] , radioimmunoassay [40, 41] or luminex technology [17, 39] . Precision of these assays regarding free and protein-bound leptin has not been reported and so may also contribute to result discrepancies across studies. Adiponectin, an adipokine closely related to leptin, has also been measured in PIVUS and ULSAM and although positively associated with coffee consumption in both cohorts, met statistical significance in the ULSAM cohort only (P = 0.03). A significant increase in plasma adiponectin levels and a nonsignificant decrease in leptin levels in response to coffee was previously reported in a 3-month coffee trial [47] . The effect of coffee on leptin, adiponectin and possibly other adipokines merits further investigation. The opposite direction of effects for coffee intake-protein and caffeine metabolite-protein relationships was unexpected in the light of the positive relationship between coffee intake and caffeine metabolite levels and that coffee consumed by Swedish is predominately of the regular type. Recently, however, Bilge et al. [48] also observed higher levels of LEP measured 3 h after regular coffee intake in a small clinical study. It is possible that the higher levels of LEP in response to acute caffeine exposure (i.e. plasma caffeine) impact appetite or other pathways which, overtime (i.e. habitual coffee intake), impact body fat and lowers LEP levels. The opposite directions may also reflect differences in the effect of caffeine and noncaffeine constitutes of coffee on LEP. Similar mechanisms may also explain the results observed for CHI3L1. Nevertheless, our caffeine metabolite-protein associations are based on PIVUS only and warrant replication.
Coffee consumption was negatively associated with CHI3L1 in PIVUS, ULSAM and EpiHealth, although the association did not reach statistical significance in ULSAM. CHI3L1, also known as YKL-40, is a member of the chitinase-like family of glycoproteins with an important role in the activation of the innate immune system [49, 50] . In humans, CHI3L1 levels are positively correlated with measures of dyslipidemia, inflammation, and obesity, as well as risk of T2D [51, 52] . Elevated CHI3L1 levels are also implicated in risk and progression of respiratory disorders, Alzheimer's disease and cancers [53] [54] [55] . Recent in vitro experiments suggest caffeine and other methylxanthines inhibit the expression and function of CHI3L1 and other chitinases by its physical interaction with the chitinase active site cleft [56] . To our knowledge, the current study is the first to suggest coffee consumption reduces plasma CHI3L1 in humans and warrants further investigation.
Of the 80 proteins examined in the current study, six have previously been investigated for relationships with habitual coffee or caffeine in humans. Our study supports the absence of an association between coffee or caffeine consumption and levels of TNF2 [57] , prolactin [58] , resistin [39] or FAS [59] . One [60] of two studies examining IGF [59, 60] reported a negative correlation between coffee intake and IGF amongst women, but not men. Zampelas et al. [61] reported a positive association between coffee consumption and IL6 levels in Greek men and women, a finding also reported in a US coffee trial [62] . In contrast, Aleksandrova et al. [43] recently reported an inverse association between coffee consumption and IL6 levels in a small casecontrol study of liver cancer. The current study, as well as one study of a Japanese population [40] , as well as a Finnish coffee trial [47] do not support an association between coffee intake and IL6.
Strengths of the current study include its sample size, the inclusion of replication samples, sevenday dietary record collection (PIVUS and ULSAM only) and breadth of precisely measured proteins. Nevertheless, several limitations, in addition to those already discussed, should be considered. Sweden is one of the world's leading nations in terms of coffee consumption per capita [13] . The demographic characteristics, coffee consumption patterns and potential confounding factor profiles of PIVUS, ULSAM and EpiHealth participants may differ from those of other populations, thus limiting the generalizability of our results. Type of coffee or method of preparation was not recorded in these cohorts. The consumption of decaffeinated coffee is very low in Sweden (<1%) [25] , and thus our associations entirely reflect those for regular coffee. The majority of coffee was filtered in Sweden before the late 2000s [25] . Boiled coffee, containing LDLraising diterpenes, could have been consumed by some ULSAM and PIVUS participants given their age and the year of blood draw (this practice was more common earlier on in Sweden). However, as the two protein-coffee associations were replicated in the contemporary EpiHealth, our findings are unlikely to reflect the diterpene content of coffee. Nevertheless, the precise chemical composition of different coffee preparations and the addition of milk and sugar was not collected uniformly across cohorts and is likely to vary within and between populations. Seven-day dietary records are arguably superior to food frequency questionnaires but may not capture the relevant period of exposure impacting protein levels [63] . However, replication in EpiHealth, which assessed longer term habitual coffee consumption but with less precision, increases the robustness of the LEP-and CHI3L1-coffee associations. The different lengths of time between coffee assessment and blood draw for proteomic measures in PIVUS, ULSAM and EpiHealth further strengthen our findings, but may have limited our discovery of coffee-protein associations more sensitive to the time of coffee exposure. We are unable to verify fasting compliance with regard to coffee as details concerning recent coffee intake prior blood draw was not specifically collected. Coffee drinking patterns are relatively stable over time, especially in the older age group [26] [27] [28] , and thus, we propose our associations result from habitual long-term coffee consumption. Finally, as in any observational study, we cannot address causality and even with our multivariable models, it is likely that some degree of residual confounding remains and could contribute to type 1 or type 2 errors.
Conclusion
In summary, our proteomic analysis of habitual coffee consumption supports an inverse association with plasma leptin and CHI3L1 levels. Pathways involving these two proteins are therefore promising and warrant further investigation. The limited number of associations observed despite breadth of clinically relevant pathways examined may also suggest that coffee may impact health by other novel pathways.
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